|
ROS1
|
ROS proto-oncogene 1, receptor tyrosine kinase |
|
- Crizotinib
- Entrectinib
- Fostamatinib
|
- Non-small cell lung cancer
|
|
RPIA
|
ribose 5-phosphate isomerase A |
- RPIA deficiency: failed conversion of R5P to RU5P
- RPIA deficiency: failed conversion of RU5P to R5P
- Pentose phosphate pathway
|
- 4-phospho-L-threonic acid
|
|
|
SELE
|
selectin E |
- Cell surface interactions at the vascular wall
|
- Carvedilol
- N-acetyl-alpha-neuraminic acid
- Endostatin
|
|
|
SERF2
|
small EDRK-rich factor 2 |
|
|
|
|
SERPINF1
|
serpin family F member 1 |
|
|
|
|
SHC1
|
SHC adaptor protein 1 |
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signalling to RAS
- Signalling to RAS
- SHC1 events in EGFR signaling
- Tie2 Signaling
- Integrin signaling
- XBP1(S) activates chaperone genes
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Constitutive Signaling by EGFRvIII
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- RET signaling
- Interleukin-15 signaling
- Interleukin-15 signaling
- Interleukin-2 signaling
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by CSF3 (G-CSF)
- Signaling by CSF3 (G-CSF)
- Signaling by CSF1 (M-CSF) in myeloid cells
|
|
|
|
SIGLEC11
|
sialic acid binding Ig like lectin 11 |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
|
|
SIGLEC12
|
sialic acid binding Ig like lectin 12 |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
|
|
SIGLEC7
|
sialic acid binding Ig like lectin 7 |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
- N-acetyl-alpha-D-glucosamine
|
|
|
SIRPA
|
signal regulatory protein alpha |
- Cell surface interactions at the vascular wall
- Signal regulatory protein family interactions
- Signal regulatory protein family interactions
- Neutrophil degranulation
|
|
|
|
SIT1
|
signaling threshold regulating transmembrane adaptor 1 |
|
|
|
|
SLAMF1
|
signaling lymphocytic activation molecule family member 1 |
|
|
|
|
SLAMF6
|
SLAM family member 6 |
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
|
|
|
|
SLC38A1
|
solute carrier family 38 member 1 |
- Astrocytic Glutamate-Glutamine Uptake And Metabolism
- Amino acid transport across the plasma membrane
|
|
|
|
SLN
|
sarcolipin |
- Ion homeostasis
- Ion transport by P-type ATPases
|
|
|
|
SOCS3
|
suppressor of cytokine signaling 3 |
- Interleukin-6 signaling
- Signaling by Leptin
- Interleukin-4 and Interleukin-13 signaling
- Interferon gamma signaling
- Regulation of IFNG signaling
- PTK6 Activates STAT3
- RUNX1 regulates transcription of genes involved in differentiation of keratinocytes
- Neddylation
- Interferon alpha/beta signaling
- Regulation of IFNA/IFNB signaling
- Signaling by CSF3 (G-CSF)
- Inactivation of CSF3 (G-CSF) signaling
- Inactivation of CSF3 (G-CSF) signaling
- Growth hormone receptor signaling
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
SOS1
|
SOS Ras/Rac guanine nucleotide exchange factor 1 |
- SOS-mediated signalling
- SOS-mediated signalling
- Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
- SHC1 events in ERBB2 signaling
- SHC1 events in ERBB4 signaling
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Signalling to RAS
- Signalling to RAS
- GRB2 events in EGFR signaling
- SHC1 events in EGFR signaling
- Downstream signal transduction
- NRAGE signals death through JNK
- GRB2 events in ERBB2 signaling
- GRB2 events in ERBB2 signaling
- Tie2 Signaling
- EGFR Transactivation by Gastrin
- DAP12 signaling
- SHC-related events triggered by IGF1R
- SHC-related events triggered by IGF1R
- Role of LAT2/NTAL/LAB on calcium mobilization
- Role of LAT2/NTAL/LAB on calcium mobilization
- FCERI mediated MAPK activation
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- NCAM signaling for neurite out-growth
- G alpha (12/13) signalling events
- Activation of RAC1
- Constitutive Signaling by EGFRvIII
- SHC-mediated cascade:FGFR1
- FRS-mediated FGFR1 signaling
- SHC-mediated cascade:FGFR2
- FRS-mediated FGFR2 signaling
- SHC-mediated cascade:FGFR3
- FRS-mediated FGFR3 signaling
- FRS-mediated FGFR4 signaling
- SHC-mediated cascade:FGFR4
- Signaling by FGFR2 in disease
- Signaling by FGFR4 in disease
- Signaling by FGFR1 in disease
- Signaling by FGFR3 in disease
- RAF/MAP kinase cascade
- Signal attenuation
- Insulin receptor signalling cascade
- Insulin receptor signalling cascade
- MET activates RAS signaling
- RET signaling
- Interleukin-15 signaling
- RAC1 GTPase cycle
- Activated NTRK2 signals through RAS
- Erythropoietin activates RAS
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK2 signals through FRS2 and FRS3
- Activated NTRK3 signals through RAS
- Interleukin receptor SHC signaling
- FLT3 Signaling
- Constitutive Signaling by Overexpressed ERBB2
- Signaling by ERBB2 KD Mutants
- Signaling by ERBB2 ECD mutants
- Signaling by ERBB2 TMD/JMD mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants
- Signaling by PDGFRA extracellular domain mutants
- Potential therapeutics for SARS
- Signaling by CSF1 (M-CSF) in myeloid cells
- Signaling by FLT3 fusion proteins
- Signaling by FLT3 ITD and TKD mutants
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
- Signaling by LTK
|
|
- Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
|
|
SPRY2
|
sprouty RTK signaling antagonist 2 |
- Spry regulation of FGF signaling
- EGFR downregulation
|
|
|
|
SRC
|
SRC proto-oncogene, non-receptor tyrosine kinase |
- Signaling by ERBB2
- Nuclear signaling by ERBB4
- Downregulation of ERBB4 signaling
- PIP3 activates AKT signaling
- GAB1 signalosome
- Downstream signal transduction
- Constitutive Signaling by Aberrant PI3K in Cancer
- Integrin signaling
- GRB2:SOS provides linkage to MAPK signaling for Integrins
- p130Cas linkage to MAPK signaling for integrins
- G alpha (s) signalling events
- G alpha (i) signalling events
- G alpha (i) signalling events
- DCC mediated attractive signaling
- DCC mediated attractive signaling
- Netrin mediated repulsion signals
- Regulation of commissural axon pathfinding by SLIT and ROBO
- RAF activation
- MAP2K and MAPK activation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF1 fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- MET activates PTK2 signaling
- InlA-mediated entry of Listeria monocytogenes into host cells
- Regulation of RUNX1 Expression and Activity
- RUNX2 regulates osteoblast differentiation
- Regulation of RUNX3 expression and activity
- Extra-nuclear estrogen signaling
- RHOU GTPase cycle
- Activated NTRK2 signals through FYN
- Activated NTRK3 signals through PI3K
- Activated NTRK3 signals through PI3K
- Long-term potentiation
- GPER1 signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by CSF1 (M-CSF) in myeloid cells
- Degradation of CDH1
|
- Dasatinib
- RU84687
- RU79256
- N6-Benzyl Adenosine-5'-Diphosphate
- RU85493
- RU78262
- Phosphonotyrosine
- Malonic acid
- RU83876
- RU90395
- RU79072
- RU78783
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- PASBN
- 2-[4-[(Z)-2-Acetamido-3-oxo-3-[[(3S)-2-oxo-1-[(4-phenylphenyl)methyl]azepan-3-yl]amino]prop-1-enyl]-2-formylphenyl]acetic acid
- PAS219
- DPI59
- RU82197
- Phenylphosphate
- RU78300
- RU79073
- RU82209
- ISO24
- RU85053
- RU78299
- Oxalic Acid
- RU78191
- Citric acid
- Paratoulene phosphate
- 4-[(4-METHYL-1-PIPERAZINYL)METHYL]-N-[3-[[4-(3-PYRIDINYL)-2-PYRIMIDINYL]AMINO]PHENYL]-BENZAMIDE
- Purvalanol A
- XL228
- Tirbanibulin
- Bosutinib
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
- 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-phenylurea
- 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
- PD-168393
- [4-({4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]quinazolin-2-yl}amino)phenyl]acetonitrile
- PP-121
- 1-cyclobutyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 1-(1-methylethyl)-3-quinolin-6-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
- 2-(4-CARCOXY-5-ISOPROPYLTHIAZOLYL)BENZOPIPERIDINE
- N-(4-PHENYLAMINO-QUINAZOLIN-6-YL)-ACRYLAMIDE
- (2E)-N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide
- Ponatinib
- Nintedanib
- Fostamatinib
|
|
|
SRSF10
|
serine and arginine rich splicing factor 10 |
- mRNA Splicing - Major Pathway
- Processing of Capped Intron-Containing Pre-mRNA
|
|
|